LU91908I2 - Telavancine, ou un de ses sels pharmaceutiquement acceptable, y compris l'hydrochlorure de telavancine (VIBATIV®) - Google Patents
Telavancine, ou un de ses sels pharmaceutiquement acceptable, y compris l'hydrochlorure de telavancine (VIBATIV®)Info
- Publication number
- LU91908I2 LU91908I2 LU91908C LU91908C LU91908I2 LU 91908 I2 LU91908 I2 LU 91908I2 LU 91908 C LU91908 C LU 91908C LU 91908 C LU91908 C LU 91908C LU 91908 I2 LU91908 I2 LU 91908I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- telavancine
- vibativ
- hydrochloride
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 title 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 108010089019 telavancin Proteins 0.000 title 1
- GSSIWSIRBWAZHG-ACOPVEIWSA-N telavancin hydrochloride Chemical compound Cl.O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O GSSIWSIRBWAZHG-ACOPVEIWSA-N 0.000 title 1
- 229940020733 vibativ Drugs 0.000 title 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical class NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 abstract 2
- 102000002068 Glycopeptides Human genes 0.000 abstract 1
- 108010015899 Glycopeptides Proteins 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
- C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21341000P | 2000-06-22 | 2000-06-22 | |
| PCT/US2001/013998 WO2001098328A2 (fr) | 2000-06-22 | 2001-05-01 | Derives phosphonates de glycopeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU91908I2 true LU91908I2 (fr) | 2012-01-30 |
Family
ID=22795013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU91908C LU91908I2 (fr) | 2000-06-22 | 2011-11-30 | Telavancine, ou un de ses sels pharmaceutiquement acceptable, y compris l'hydrochlorure de telavancine (VIBATIV®) |
Country Status (36)
| Country | Link |
|---|---|
| US (10) | US6635618B2 (fr) |
| EP (1) | EP1292612B1 (fr) |
| JP (2) | JP3900491B2 (fr) |
| KR (1) | KR100768488B1 (fr) |
| CN (1) | CN100469788C (fr) |
| AR (1) | AR035333A1 (fr) |
| AT (1) | ATE337334T1 (fr) |
| AU (2) | AU2001261107B2 (fr) |
| BR (1) | BRPI0111222B8 (fr) |
| CA (2) | CA2713965A1 (fr) |
| CY (2) | CY1105194T1 (fr) |
| CZ (1) | CZ303672B6 (fr) |
| DE (2) | DE60122516T2 (fr) |
| DK (1) | DK1292612T3 (fr) |
| EA (1) | EA005953B1 (fr) |
| EG (1) | EG26726A (fr) |
| ES (1) | ES2271012T3 (fr) |
| HK (1) | HK1052191B (fr) |
| HR (1) | HRP20020888B1 (fr) |
| HU (2) | HU229370B1 (fr) |
| IL (1) | IL152408A (fr) |
| IS (1) | IS2303B (fr) |
| LU (1) | LU91908I2 (fr) |
| MX (1) | MXPA02012745A (fr) |
| MY (1) | MY127081A (fr) |
| NO (2) | NO330360B1 (fr) |
| NZ (1) | NZ522279A (fr) |
| PL (1) | PL207101B1 (fr) |
| PT (1) | PT1292612E (fr) |
| RS (1) | RS50499B (fr) |
| SI (1) | SI1292612T1 (fr) |
| SK (1) | SK287470B6 (fr) |
| TW (1) | TWI305209B (fr) |
| UA (1) | UA75083C2 (fr) |
| WO (1) | WO2001098328A2 (fr) |
| ZA (1) | ZA200209419B (fr) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2201825T3 (es) * | 1998-12-23 | 2004-03-16 | Theravance, Inc. | Derivados del glicopeptidos y composiciones farmaceuticas que los contienen. |
| AU2001259298A1 (en) | 2000-05-02 | 2001-11-12 | Advanced Medicine, Inc. | Polyacid glycopeptide derivatives |
| DE60136926D1 (de) | 2000-05-02 | 2009-01-22 | Theravance Inc | Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält |
| WO2001098329A1 (fr) | 2000-06-22 | 2001-12-27 | Theravance, Inc. | Derives polyhydroxy de glycopeptides |
| UA75083C2 (uk) * | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| US6872804B2 (en) | 2000-06-22 | 2005-03-29 | Theravance, Inc. | Glycopeptide disulfide and thioester derivatives |
| ATE388960T1 (de) | 2000-06-22 | 2008-03-15 | Theravance Inc | Glykopeptidderivate mit carboxysacchariden |
| TWI275594B (en) * | 2001-08-24 | 2007-03-11 | Theravance Inc | Process for preparing vancomycin phosphonate derivatives |
| TWI312785B (en) * | 2001-08-24 | 2009-08-01 | Theravance Inc | Process for preparing vancomycin derivatives |
| TWI233932B (en) | 2001-08-24 | 2005-06-11 | Theravance Inc | Process for purifying glycopeptide phosphonate derivatives |
| WO2003099858A1 (fr) | 2002-05-24 | 2003-12-04 | Theravance, Inc. | Antibiotiques a base de cephalosporine glycopeptidique reticulee |
| WO2003106399A2 (fr) | 2002-06-17 | 2003-12-24 | Theravance, Inc. | Procede de preparation de composes aldehydes $g(b)-amino <i>n</i>-proteges |
| JP2006528704A (ja) * | 2003-05-27 | 2006-12-21 | セラヴァンス インコーポレーテッド | グリコペプチド抗細菌剤と組み合わせたポリエンマクロライド抗真菌剤の使用 |
| EP1654036B1 (fr) | 2003-07-22 | 2007-12-26 | Theravance, Inc. | Utilisation d'un agent antifongique a base d'echinocandines conjointement avec un agent antibacterien glycopeptidique |
| TWI342312B (en) * | 2003-10-22 | 2011-05-21 | Theravance Inc | Hydrochloride salts of a glycopeptide phosphonate derivative |
| US7429575B2 (en) * | 2006-01-10 | 2008-09-30 | Yu Ruey J | N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use |
| JP2008112847A (ja) * | 2006-10-30 | 2008-05-15 | Shin Etsu Chem Co Ltd | 単結晶シリコン太陽電池の製造方法及び単結晶シリコン太陽電池 |
| US8946144B2 (en) | 2006-12-22 | 2015-02-03 | The Medicines Company | Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections |
| US20090069219A1 (en) * | 2007-09-09 | 2009-03-12 | Protia, Llc | Deuterium-enriched telavancin |
| WO2009061208A1 (fr) * | 2007-11-09 | 2009-05-14 | Pronova Biopharma Norge As | Composés lipidiques à utiliser dans des produits cosmétiques, en tant que suppléments alimentaires ou en tant que médicaments |
| WO2009085562A1 (fr) * | 2007-12-26 | 2009-07-09 | Lead Therapeutics, Inc. | Nouveaux glycopeptides semi-synthétiques comme agents antibactériens |
| EP2147910A1 (fr) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Nouveaux composés lipidiques |
| WO2010048340A2 (fr) * | 2008-10-24 | 2010-04-29 | Lead Therapeutics, Inc. | Nouveaux glycopeptides semi-synthétiques en tant qu'agents antibactériens |
| GB2465863A (en) * | 2008-12-05 | 2010-06-09 | Lead Therapeutics Inc | Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections |
| CN102573882A (zh) | 2009-04-28 | 2012-07-11 | 塔尔甘塔治疗公司 | 用奥利万星治疗细菌感染的方法 |
| NZ596386A (en) | 2009-05-08 | 2014-01-31 | Pronova Biopharma Norge As | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas |
| WO2011005959A1 (fr) * | 2009-07-09 | 2011-01-13 | Plus Chemicals Sa | Procédé de fabrication de décylaminoéthanal n-protégé |
| UA111475C2 (uk) | 2010-11-05 | 2016-05-10 | Пронова Байофарма Нордж Ас | Способи лікування із застосуванням ліпідних сполук |
| WO2013034675A1 (fr) | 2011-09-09 | 2013-03-14 | Sandoz Ag | Procédé de synthèse de télavancine et de ses sels pharmaceutiquement acceptables et dérivés n-protégés correspondants |
| EP2753637A1 (fr) | 2011-09-09 | 2014-07-16 | Sandoz AG | Procédé de synthèse de télavancine et de ses sels pharmaceutiquement acceptables et dérivé imine n-protégé de télavancine |
| JP5724937B2 (ja) * | 2012-04-23 | 2015-05-27 | ニプロ株式会社 | 腎臓集積性を示すペプチド、製剤 |
| CN103897040B (zh) * | 2012-12-27 | 2018-05-22 | 浙江医药股份有限公司新昌制药厂 | 新型糖肽类化合物或其药用盐及其制备方法、以及药物组合物和用途 |
| WO2014132134A1 (fr) | 2013-02-28 | 2014-09-04 | Pronova Biopharma Norge As | Composition comprenant un composé lipidique, un triglycéride et un tensioactif, et procédés d'utilisation associés |
| WO2014152332A1 (fr) | 2013-03-15 | 2014-09-25 | Melinta Therapeutics, Inc. | Procédés de traitement d'infections chez des patients atteints de surpoids et d'obésité utilisant d'antibiotiques |
| CN105085636B (zh) * | 2014-05-19 | 2020-05-01 | 中国医学科学院药物研究所 | 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用 |
| CN107257689A (zh) | 2015-02-23 | 2017-10-17 | 施万生物制药抗生素Ip有限责任公司 | 投予特拉万星(telavancin)的剂量和方法 |
| KR20240033300A (ko) | 2015-04-28 | 2024-03-12 | 바스프 에이에스 | 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도 |
| CN106188243B (zh) * | 2015-05-05 | 2020-06-26 | 博瑞生物医药（苏州）股份有限公司 | 一种奥利万星的制备方法 |
| US20200171124A1 (en) | 2016-04-15 | 2020-06-04 | Lupin Limited | Topical compositions for ophthalmic and otic use |
| EA201892413A1 (ru) | 2016-05-09 | 2019-05-31 | Кселлия Фармасьютикалз Апс | Стабилизированные препараты гликопептидного антибиотика |
| CA3062570A1 (fr) * | 2017-05-22 | 2018-11-29 | Insmed Incorporated | Derives clivables de lipo-glycopeptides et leurs utilisations |
| CN107629115B (zh) * | 2017-09-08 | 2021-05-07 | 福建省微生物研究所 | 一种特拉万星的纯化方法 |
| CN107629116B (zh) * | 2017-09-08 | 2021-05-07 | 福建省微生物研究所 | 一种特拉万星的纯化方法 |
| CN107987131B (zh) * | 2017-11-16 | 2021-03-09 | 上海来益生物药物研究开发中心有限责任公司 | 一组具有抗耐药性细菌活性的化合物、其制备方法和应用 |
| EP3720431B1 (fr) | 2017-12-06 | 2024-10-30 | Basf As | Dérivés d'acide gras pour le traitement de la stéatohépatite non alcoolique |
| CN108409837B (zh) * | 2018-03-06 | 2021-09-24 | 上海来益生物药物研究开发中心有限责任公司 | 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用 |
| US20220024980A1 (en) * | 2018-11-21 | 2022-01-27 | Insmed Incorporated | Lipo-glycopeptide cleavable derivatives and uses thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6872A (en) * | 1849-11-13 | Means of changing the combination in bevolving tumbler-locks | ||
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4698327A (en) | 1985-04-25 | 1987-10-06 | Eli Lilly And Company | Novel glycopeptide derivatives |
| US4639433A (en) * | 1985-08-14 | 1987-01-27 | Eli Lilly And Company | Glycopeptide derivatives |
| US4643987A (en) | 1985-08-14 | 1987-02-17 | Eli Lilly And Company | Modified glycopeptides |
| US4885275A (en) * | 1987-10-15 | 1989-12-05 | Eli Lilly And Company | Vancomycin-HCL solutions and the lyophilization thereof |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| ZA909847B (en) * | 1989-12-13 | 1992-08-26 | Lilly Co Eli | Glycopeptide derivatives |
| US5750509A (en) | 1991-07-29 | 1998-05-12 | Gruppo Lepetit S.P.A. | Amide derivatives of antibiotic A 40926 |
| US5217493A (en) * | 1992-03-11 | 1993-06-08 | Board Of Regents, The University Of Texas System | Antibacterial coated medical implants |
| US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| JPH08503951A (ja) | 1992-12-02 | 1996-04-30 | インサイト・ビジョン・インコーポレイテッド | シクロデキストリンとポリマーを用いた薬剤供給系 |
| US6077822A (en) * | 1993-09-14 | 2000-06-20 | Dumex-Alpharma A/S | Drug salts |
| US5840684A (en) | 1994-01-28 | 1998-11-24 | Eli Lilly And Company | Glycopeptide antibiotic derivatives |
| TW457248B (en) | 1994-01-28 | 2001-10-01 | Lilly Co Eli | Glycopeptide antibiotic derivatives |
| US5614615A (en) | 1995-03-21 | 1997-03-25 | The Scripps Research Institute | Sialyl Lewis X mimetics incorporating fucopeptides |
| US5919756A (en) | 1996-06-28 | 1999-07-06 | Eli Lilly And Company | Amides |
| US5916873A (en) | 1997-04-17 | 1999-06-29 | Eli Lilly And Company | Teicoplanin derivatives |
| EP1025852A4 (fr) * | 1997-10-03 | 2001-11-07 | Fujisawa Pharmaceutical Co | Chlorhydrates de vancomycines antibiotiques et leur procede de production |
| US6323176B1 (en) * | 1998-02-25 | 2001-11-27 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| JP2002520422A (ja) * | 1998-07-14 | 2002-07-09 | プリンストン ユニバーシティ | グリコペプチド抗生物質、グリコペプチド抗生物質のコンビナトリアルライブラリーおよびその作成方法 |
| ES2201825T3 (es) * | 1998-12-23 | 2004-03-16 | Theravance, Inc. | Derivados del glicopeptidos y composiciones farmaceuticas que los contienen. |
| DE19911097A1 (de) | 1999-03-12 | 2000-09-14 | Basf Ag | Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen |
| WO2000059528A1 (fr) | 1999-04-02 | 2000-10-12 | The Trustees Of Princeton University | Antibiotiques glycopeptidiques des-leucyl et procede de preparation |
| JP2000302687A (ja) | 1999-04-22 | 2000-10-31 | Sagami Chem Res Center | 抗菌性オリゴマー及び抗菌剤 |
| DE60136926D1 (de) | 2000-05-02 | 2009-01-22 | Theravance Inc | Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält |
| AU2001259298A1 (en) | 2000-05-02 | 2001-11-12 | Advanced Medicine, Inc. | Polyacid glycopeptide derivatives |
| WO2001097851A2 (fr) | 2000-06-21 | 2001-12-27 | Cubist Pharmaceuticals, Inc. | Compositions et methodes visant a ameliorer l'absorption orale d'agents anti-microbiens |
| ATE388960T1 (de) | 2000-06-22 | 2008-03-15 | Theravance Inc | Glykopeptidderivate mit carboxysacchariden |
| AU2001259302A1 (en) | 2000-06-22 | 2002-01-02 | Yongqi Mu | Glycopeptide disulfide and thioester derivatives |
| WO2001098329A1 (fr) | 2000-06-22 | 2001-12-27 | Theravance, Inc. | Derives polyhydroxy de glycopeptides |
| UA75083C2 (uk) * | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| TWI233932B (en) * | 2001-08-24 | 2005-06-11 | Theravance Inc | Process for purifying glycopeptide phosphonate derivatives |
| TWI275594B (en) * | 2001-08-24 | 2007-03-11 | Theravance Inc | Process for preparing vancomycin phosphonate derivatives |
-
2001
- 2001-01-05 UA UA2003010499A patent/UA75083C2/uk unknown
- 2001-04-27 MY MYPI20012000 patent/MY127081A/en unknown
- 2001-04-29 EG EG2001040429A patent/EG26726A/en active
- 2001-04-30 AR ARP010102060A patent/AR035333A1/es active IP Right Grant
- 2001-05-01 PL PL359419A patent/PL207101B1/pl unknown
- 2001-05-01 BR BRPI0111222A patent/BRPI0111222B8/pt not_active IP Right Cessation
- 2001-05-01 DK DK01934967T patent/DK1292612T3/da active
- 2001-05-01 EP EP01934967A patent/EP1292612B1/fr not_active Expired - Lifetime
- 2001-05-01 HU HU0301320A patent/HU229370B1/hu not_active IP Right Cessation
- 2001-05-01 AT AT01934967T patent/ATE337334T1/de active
- 2001-05-01 ES ES01934967T patent/ES2271012T3/es not_active Expired - Lifetime
- 2001-05-01 HK HK03104490.4A patent/HK1052191B/en not_active IP Right Cessation
- 2001-05-01 IL IL152408A patent/IL152408A/en unknown
- 2001-05-01 RS YUP-969/02A patent/RS50499B/sr unknown
- 2001-05-01 CA CA2713965A patent/CA2713965A1/fr not_active Abandoned
- 2001-05-01 WO PCT/US2001/013998 patent/WO2001098328A2/fr not_active Ceased
- 2001-05-01 US US09/847,042 patent/US6635618B2/en not_active Expired - Lifetime
- 2001-05-01 AU AU2001261107A patent/AU2001261107B2/en not_active Expired
- 2001-05-01 MX MXPA02012745A patent/MXPA02012745A/es active IP Right Grant
- 2001-05-01 JP JP2002504283A patent/JP3900491B2/ja not_active Expired - Fee Related
- 2001-05-01 KR KR1020027017472A patent/KR100768488B1/ko not_active Expired - Lifetime
- 2001-05-01 AU AU6110701A patent/AU6110701A/xx active Pending
- 2001-05-01 NZ NZ522279A patent/NZ522279A/en not_active IP Right Cessation
- 2001-05-01 SI SI200130642T patent/SI1292612T1/sl unknown
- 2001-05-01 EA EA200300050A patent/EA005953B1/ru not_active IP Right Cessation
- 2001-05-01 TW TW090110397A patent/TWI305209B/zh not_active IP Right Cessation
- 2001-05-01 HR HR20020888A patent/HRP20020888B1/xx not_active IP Right Cessation
- 2001-05-01 CZ CZ20023942A patent/CZ303672B6/cs not_active IP Right Cessation
- 2001-05-01 CN CNB018113508A patent/CN100469788C/zh not_active Expired - Lifetime
- 2001-05-01 DE DE60122516T patent/DE60122516T2/de not_active Expired - Lifetime
- 2001-05-01 PT PT01934967T patent/PT1292612E/pt unknown
- 2001-05-01 SK SK1852-2002A patent/SK287470B6/sk not_active IP Right Cessation
- 2001-05-01 CA CA2411590A patent/CA2411590C/fr not_active Expired - Lifetime
-
2002
- 2002-10-29 IS IS6600A patent/IS2303B/is unknown
- 2002-11-19 ZA ZA200209419A patent/ZA200209419B/en unknown
- 2002-12-11 NO NO20025954A patent/NO330360B1/no not_active IP Right Cessation
-
2003
- 2003-05-12 US US10/436,341 patent/US6872701B2/en not_active Expired - Lifetime
- 2003-09-24 US US10/669,778 patent/US6887976B2/en not_active Expired - Lifetime
-
2005
- 2005-01-18 US US11/037,934 patent/US7008923B2/en not_active Expired - Lifetime
- 2005-11-02 US US11/265,570 patent/US7208471B2/en not_active Expired - Lifetime
-
2006
- 2006-09-04 CY CY20061101256T patent/CY1105194T1/el unknown
- 2006-10-23 US US11/584,908 patent/US7351691B2/en not_active Expired - Lifetime
- 2006-11-09 JP JP2006304562A patent/JP2007045842A/ja active Pending
-
2007
- 2007-10-24 US US11/977,429 patent/US7700550B2/en not_active Expired - Fee Related
-
2010
- 2010-03-02 US US12/715,554 patent/US8101575B2/en not_active Expired - Fee Related
-
2011
- 2011-11-18 NO NO2011025C patent/NO2011025I1/no not_active IP Right Cessation
- 2011-11-30 DE DE201112100062 patent/DE122011100062I1/de active Pending
- 2011-11-30 LU LU91908C patent/LU91908I2/fr unknown
- 2011-12-16 US US13/328,284 patent/US8541375B2/en not_active Expired - Fee Related
-
2012
- 2012-02-02 CY CY2012006C patent/CY2012006I1/el unknown
-
2013
- 2013-07-17 US US13/944,193 patent/US8859506B2/en not_active Expired - Fee Related
-
2014
- 2014-04-15 HU HUS1400024C patent/HUS1400024I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU91908I2 (fr) | Telavancine, ou un de ses sels pharmaceutiquement acceptable, y compris l'hydrochlorure de telavancine (VIBATIV®) | |
| NO20006323D0 (no) | Glykopeptidderivater og farmasöytiske sammensetninger som inneholder disse | |
| HRP20041084B1 (hr) | C-aril glukozid inhibitori sglt2 i postupak | |
| DK0920421T3 (da) | Isoxazolinderivater anvendelige som antimikrobielle midler | |
| NO20022888L (no) | Lipopeptider som antibakterielle midler | |
| BG106366A (en) | Moxifloxacin formulation containing common salt | |
| NO20022887L (no) | Lipopeptider som antibakterielle midler | |
| ATE388960T1 (de) | Glykopeptidderivate mit carboxysacchariden | |
| WO2003053971A8 (fr) | Antiviraux a base de pyridoquinoxaline | |
| EE200300129A (et) | Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine | |
| DK1073447T3 (da) | N1-modificerede glycopeptider | |
| CY1105598T1 (el) | Μεθοδοι για την παρασκευη αντιβακτηριακων παραγοντων τυπου carbapenem | |
| NZ504614A (en) | Echinocandin derivatives and application as anti-fungal agents | |
| PT1358159E (pt) | Tartrato e fosfato de 3,4 diaminopiridina, as suas composições farmacêuticas e as suas utilizações | |
| PT1181300E (pt) | Derivados 6-o-carbamato de cetolido | |
| CA2420056A1 (fr) | 1-amino-alkylcyclohexanes en tant qu'agents trypanocidaux | |
| TWI231815B (en) | Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents | |
| IT1301967B1 (it) | Derivato di eritromicina ad attivita' antibiotica | |
| TH77750A (th) | อนุพันธ์ไกลโคเปปไทด์ฟอสโฟเนท |